Skip to main content
NewslettersWatchlist

Black Diamond Therapeutics Inc(BDTX-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low4.85
Day High5.33
Open:5.25
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Barchart
Stocks Set to Open Lower as Investors Await U.S. Inflation Data and Big Bank Earnings, Chinese Inflation Data Disappoints
Motley Fool
Why Shares of Black Diamond Therapeutics Skyrocketed This Week
Spotlight Growth
Black Diamond Therapeutics’ (NASDAQ: BDTX) BDTX-1535 Proves Promising for EGFR Mutated NSCLC and GBM
Globe Newswire
Black Diamond Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Globe Newswire
Black Diamond Therapeutics to Present at the 2022 Wedbush PacGrow Healthcare Virtual Conference
Globe Newswire
Black Diamond Therapeutics Appoints Sergey Yurasov, M.D., Ph.D., as Chief Medical Officer
Globe Newswire
Black Diamond Therapeutics to Present at the H.C. Wainwright Global Investment Conference
Globe Newswire
Black Diamond Therapeutics Announces Publication of New Computational and Functional Analyses of HER2 Mutations Based on its Proprietary MAP Discovery Engine
Globe Newswire
Black Diamond Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
Globe Newswire
Black Diamond Therapeutics Announces Pipeline Prioritization and Workforce Realignment
Globe Newswire
Black Diamond Therapeutics Announces First Patient Dosed in Phase 1 Study of BDTX-1535, a MasterKey Inhibitor of EGFR for the Treatment of Glioblastoma and Non-Small Cell Lung Cancer
Globe Newswire
Black Diamond Therapeutics to Present at the Canaccord Genuity Horizons in Oncology Virtual Conference
Globe Newswire
Black Diamond Therapeutics Appoints Wendy L. Dixon to its Board of Directors
Globe Newswire
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
Globe Newswire
Black Diamond Therapeutics to Participate at the Cowen 42nd Annual Health Care Conference
Globe Newswire
Black Diamond Therapeutics Appoints Elizabeth Montgomery as Chief People Officer
Globe Newswire
Black Diamond Therapeutics Announces FDA Allowance of IND Application for BDTX-1535, A MasterKey Inhibitor of EGFR for the Treatment of Gliobastoma and Non-Small Cell Lung Cancer
Globe Newswire
Black Diamond Therapeutics Announces Strategic Priorities and Expected Milestones for 2022
Globe Newswire
Black Diamond Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Globe NewsWire
Black Diamond Therapeutics to Present Pre-Clinical Data on BDTX-1535, BRAF, and FGFR Programs at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Globe NewsWire
Black Diamond Therapeutics to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference
Globe NewsWire
Black Diamond Therapeutics and OpenEye Scientific Announce Collaboration to Expand MAP Drug Discovery Platform
Globe NewsWire
Black Diamond Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update
Globe NewsWire
Black Diamond Therapeutics Announces Appointment of Mark Velleca, M.D., Ph.D. to Board of Directors
Globe NewsWire
Black Diamond Therapeutics to Present at Upcoming Investor Conferences
Globe NewsWire
Black Diamond Therapeutics Presents Phase 1 Pharmacokinetic, Safety, and Preliminary Efficacy Data of BDTX-189 in Advanced Solid Tumors Harboring EGFR or HER2 Alterations
Globe NewsWire
Black Diamond Therapeutics to Host Webcast Presentation of Data From Phase 1 Dose-Escalation Portion of MasterKey-01 Clinical Trial
Globe NewsWire
Black Diamond Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update
Globe NewsWire
Black Diamond Therapeutics to Present Phase 1 BDTX-189 Data in Advanced Solid Tumors at American Society of Clinical Oncology
Globe NewsWire
Black Diamond Therapeutics Announces Preclinical Data Presentations on BDTX-189 and BDTX-1535 at American Association for Cancer Research Annual Meeting
Globe NewsWire
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
Globe NewsWire
Black Diamond Therapeutics to Present Pre-Clinical Data on BDTX-189 and BDTX-1535 at American Association for Cancer Research Annual Meeting

Profile

Black Diamond Therapeutics Inc. is an oncology medicine company. It engages in discovery and development of small molecule, tumor-agnostic therapies. The company's lead product candidate is BDTX-189, an inhibitor of non-canonical and oncogenic mutations of ErbB kinases epidermal growth factor receptor and tyrosine-protein kinase. Black Diamond Therapeutics Inc. is based in Cambridge, Massachusetts.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.